Keyword: Shire

Servier hired a Shire executive to oversee its new U.S. unit that it will build out of the oncology business it is buying from Shire for $2.4 billion.

Takeda's $585 million Chinese revenue for FY2017 was only one-tenth of what it collected from Japan, and buying Shire won't change that soon.

J&J and Allergan are among the pharma companies mulling both acquisitions and selloffs, signaling that the M&A boom will continue through 2018.

Takeda investors worry about Shire's hemophilia products; Biocon's biosimilars plant clears the FDA; C-Bridge Capital invests $35 million in Nuance.

Spectrum Pharma—a rare disease and cancer specialist with six marketed drugs and $116 million in annual sales—is eyeing a sale, Bloomberg says. 

Investors opposing Takeda’s $62 billion buyout of Shire worry that Shire's hemophilia drug sales will be undercut by new gene offerings.

Shire has won approval to transfer production of an important replacement therapy to a plant in Georgia that it got in its 2016 buyout of Baxalta.

Shire's ability to market Cinryze for children as young as 6 with HAE. That could help Shire fend off an all-out attack from CSL.

Takeda shareholders who oppose the company’s $62 billion buyout of Shire are gaining support for their effort to block the deal.

Takeda's loss of market value is being cited by a group of 12 shareholders stepping up to oppose its acquisition of Shire.